The aim of this study was to assess the quality and scope of the current cost-effectiveness analysis (CEA) literature in the field of hand and upper limb orthopaedic surgery.
The cost-effectiveness analysis (CEA) is a common way to assess the value of an intervention relative to a comparator, in economic evaluation of medical care, by assessing differences in costs and subsequent quality of life.
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In orthopaedics, previous systematic reviews have assessed CEAs across sports 2 and trauma, 3 finding the overall quality of studies to be good in these subspecialties. However, there has been no systematic examination of CEAs in upper limb surgery. Brauer et al 4, 5 conducted two separate studies evaluating the quality of CEAs across all orthopaedic subspecialties from 1976 to 2001 and included only five hand and upper limb studies. No subgroup analyses were conducted on these studies.
Cost-effectiveness plays an important role in upper limb surgery, where a patient's level of function can have direct and indirect effects on quality of life. 6 Very little is known about the scope and quality of the CEA literature in hand and upper limb surgery. Our goal was to conduct a systematic review to: 1) assess the quality and scope of the current CEAs on hand and upper limb surgery; 2) identify areas for further economic evaluation in these fields; and 3) identify opportunities for quality improvement.
Materials and Methods
Overview. This review focuses on cost-utility analyses, which measure health outcomes in quality-adjusted life-years (QALYs) that incorporate subjective valuations of health states by patients. 2, 5, 7 Cost-utility analyses use an incremental cost-effectiveness ratio (ICER), which represents the difference in costs divided by the difference in QALYs between two interventions.
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ICERs are evaluated against a willingness-to-pay (WTP) threshold, which represents the maximum expenditure that society is willing to make to obtain an additional QALY, commonly $50 000 or $100 000 per QALY. 8 If a procedure's ICER falls  SYSTEMATIC REVIEW
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below the WTP threshold, it can be considered a cost-effective alternative to its comparator. Search and inclusion criteria. The systematic review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist. 9 We employed a systematic search of MEDLINE as well as the Cost-Effectiveness Analysis (CEA) Registry by the Center for the Evaluation of Value and Risk in Health at Tufts University.
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This CEA registry is a well-established and high-quality repository of CEAs. 11, 12 The registry possesses over 5600 cost-utility analyses and incorporates strict inclusion criteria for papers that are published in English, are CEAs, and measure health benefits in QALYs. The registry excludes reviews, editorials, and methodological articles. We used a supplementary MEDLINE search to capture any studies that met the above inclusion criteria but were not yet included within the CEA registry.
We included studies from the CEA Registry with a keyword pertaining to upper limb anatomy. Our MEDLINE search incorporated any study pertaining to upper limb anatomy, conducted on or after 1 January 1997, and using the terms quality-adjusted life-years (QALYs) and costs. From our preliminary searches, studies were included if they: 1) examined a procedure relating to orthopaedic upper limb surgery; 2) were clinical; and 3) adhered to methodology consistent with a cost-utility analysis.
Our rationale for including a time limit in our search was based on the recommendations of the First Panel on CostEffectiveness in Health and Medicine, published on 16 October 1996, which outlined the first consensus-based guidelines for the conduct of CEAs.
1 We restricted our search from the start of January 1997 to the end of December 2016 to allow adequate time for studies to reflect the guidelines. We restricted our review to clinical studies, which are cost-utility analyses conducted with any form of patient data, derived either from a sample of actual patients or using previously published datasets. We therefore excluded any editorials, reviews, or methodological studies. Additionally, we excluded studies focusing on nonoperative interventions without including a surgical/procedural comparator. We excluded CEAs not incorporating QALYs, cost-benefit analyses, or cost-minimization analyses. 13 We restricted our search to studies conducted in humans and in English language only for ease of interpretation. Although a language restriction can possess bias, there is no evidence that it has any effects on resultant data in systematic reviews and meta-analyses.
14 CEA Registry search. The CEA Registry screening process was searched by "[Anatomic location]." Anatomical location terms included the broad term "upper extremity" and more specific anatomical regions pertinent to upper limb clinical anatomy: shoulder, glenohumeral, labrum, humerus, elbow, wrist, radius, ulna, scaphoid, carpal, hand, thumb, finger, metacarpal, carpometacarpal, metacarpophalangeal, phalanx, phalanges, intermetacarpal, and interphalangeal. Additionally, we included terms specific to anatomical injuries: "rotator cuff" and "carpal tunnel syndrome." The CEA Registry yielded a total of 134 studies. MEDLINE search. The PubMed interface was used to search the MEDLINE database. Search terms were grouped into three broad categories: [ These 169 total studies independently underwent a combined title and abstract screening, followed by a full text screening separately by two authors (PVR and RAQ) to ensure full adherence to the inclusion criteria. This resulted in 33 studies suitable for inclusion in this review (Fig. 1) . Quality scoring and data extraction. We assigned a quality score to each study using the Quality of Health Economic Analysis (QHES) scale. 15 The QHES scale ranges from 0 to 100; although there is no standard for the QHES score, a score above 75 is considered high-quality. 15 Each of the 33 studies underwent comprehensive paper review by the primary author (PVR), followed by independent review by the secondary author (RAQ) of a random sampling of 20% of these studies identified by a random number generator to ensure at least 90% inter-rater agreement.
We also recorded the following study characteristics: study design (CEA conducted alongside a randomized-controlled trial or a prospective cohort study, decision tree, Markov cohort, or microsimulation); lowest level of evidence used to derive health state transition probabilities ("level I" for randomized-controlled trials, "level II" for prospective cohort studies, "level III" for retrospective studies, or "level IV" for case series); whether the study reported an ICER; perspective ("healthcare payer" or "societal," where societal perspective incorporates unpaid and informal healthcare costs); time horizon lengths; sensitivity analyses conducted ("deterministic" for parameter variations over a range or "probabilistic" for variations conducted over a distribution); and utility assessment ("direct" if the study elicited health-state preferences using tools such as time tradeoff, standard gamble, or visual analogue scales, or "indirect" if the study used tools such as EuroQol (EQ-5D) 16, 17 or 36-Item Short-Form Health Survey (SF-36)). 18, 19 Statistical analysis. QHES scores extracted from each study were averaged across all studies, and by anatomical region and time frame. We used frequencies to describe the distributions of study characteristics, and we calculated means for study characteristics expressed by continuous factors (e.g. time horizon).
We conducted the analysis for the overall sample and stratified by anatomical region, time period, and geographic region to elucidate any trends. We extracted ICERs from studies, when available, and adjusted to 2016 US Dollars using the Consumer Price Index 20 and 2016 United Kingdom Pounds using Bank of England inflation values.
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Results
Overview. Table I provides an overview of the 33 CEAs screened for inclusion in this review.
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Study characteristics. Table II provides the general study characteristics for the 33 studies. All anatomical categories have a collection of model-based and randomized controlled trial (RCT)-based study designs. All RCT-based studies have been conducted in the United Kingdom, Australia, or Europe whereas most (95%) decision tree, Markov cohort, and microsimulation designs have been conducted in the United States or Canada.
Studies from the United States predominantly use a societal perspective (n = 12, 70.6%) whereas studies from the United Kingdom predominantly use a healthcare payer perspective (n = 5, 55.6%). When stratified by year of publication, there is a trend towards shorter period of inclusion in recent years; for example, CEAs from 2015 to 2016 demonstrate a range of only RCT £119 049 £20 000 Addition of botulinum toxin A to a therapy programme for upper-limb post-stroke spasticity was not cost-effective.
*All values given per quality-adjusted life-year †Cost-effectiveness analysis conducted alongside a cohort or series of patients followed prospectively for data on outcomes ‡Adjusting ICER to 2016 values raised the ratio above the corresponding willingness-to-pay threshold ICER, incremental cost-effectiveness ratio; WTP, willingness-to-pay threshold; Prosp., prospective cohort; N/A, not available; QALYs, quality-adjusted life-years; RCT, randomized controlled trial; Microsim., microsimulation; DT, decision tree; HUI, health utility index; SF-36, 36-Item Short-Form Health Survey EQ-5D, EuroQol-5D; ORIF, open reduction internal fixation; OR, operating room; TWA, total wrist arthroplasty one to two years. In 47% of all studies (n = 8) from the United States and all studies (n = 3) from Canada, direct utility measurements such as time trade-off, standard gamble, or visual analogue scales were used. However, all studies from the United Kingdom, Australia, and Europe utilize indirect utility measurement tools such as EQ-5D, SF-36, or health utility index (HUI).
Of the studies from the United States, 13 (77%) use deterministic analyses only, whereas six (67%) of studies from the United Kingdom applied both deterministic and probabilistic sensitivity analyses. Of the 28 studies with a statement of funding, 12 were funded by public funds, five by private funds, two by both, and nine did not specify. We found studies conducted in the United States used a wide range of WTP thresholds ($4836 per QALY to $100 000 per QALY) while studies conducted in the United Kingdom tend to use standard WTP thresholds of £20 000 to £30 000. Study quality. The mean total QHES score for all 33 studies is 82 (high-quality). When stratified according to anatomical group, the QHES scores are: 77 shoulder; 87 arm; 78 elbow; 85 forearm; 86 hand and wrist; and 91 general upper limb. Figure 2 demonstrates an increase in the number of upper-limb CEAs published since 1997. Over time, a greater proportion of these studies have demonstrated poorer QHES quality (scores < 75), with scores as low as 41. Studies with lower scores failed to identify reference case perspectives; incorporate ICERs and sensitivity analyses; discount costs and utilities; and include a statement of funding or support (Table II) .
Discussion
Since the First Panel Recommendations were published in 1997, the overall quality of cost-effectiveness literature within the field of upper limb orthopaedic surgery has been high. When stratified by each anatomical region of study, the mean QHES score is still > 75. However, there has been a greater proportion of studies demonstrating lower-quality scores in recent years. Lower scores < 75 tend to demonstrate several deficits including failures in identifying reference case perspectives; incorporating comparators, ICERs, and sensitivity analyses; discounting costs and utilities; and including a statement of funding or support.
Reviews within the subspecialties of sports medicine 2 and trauma 3 have found the quality to be strong, with QHES means of 81.8 and 79.25, respectively. Brauer et al 5 noted more orthopaedic studies complying with the recommendations of the First Panel after 1998. Our study, however, seems to indicate a divergence in the quality of the upper limb orthopaedic cost-effectiveness literature since then. Given this increasing variability, the new recommendations from the Second Panel on Cost-Effectiveness in Health and Medicine published in October 2016 are timely to re-establish standard methodological practices. 55 Our review identified the shoulder and wrist to be the anatomical areas of considerable cost-effectiveness research, with emphasis on rotator cuff tears and carpal tunnel syndrome given their procedural prevalence. Studies in this review have supported single-row, arthroscopic rotator cuff repairs to be more cost-effective alternatives to nonoperative, open, or double-row procedures, [22] [23] [24] and endoscopic carpal tunnel release to be a more cost-effective option than open release when both techniques are performed in outpatient settings. 25, 26 There is, however, a paucity of cost-utility analyses of the elbow and of paediatric upper limb pathologies.
Studies conducted in the United States tend to follow decision tree or Markov models with societal perspectives. All analyses The United States experience has been far more limited, with political resistance to incorporation of CEAs in federal coverage decisions. 59 The Second Panel's efforts represent an effort to standardize CEAs across countries for ease of comparability. In addition, the Second Panel's recommendation to consider both healthcare payer and societal perspectives represents an acknowledgment of the importance of both direct and indirect costs to patients. Accounting for unpaid patient costs of lost productivity and unpaid caregiving can provide better insight into how health interventions can affect future patient income and societal productivity.
This review should be viewed in light of its limitations. Given the stringent inclusion criteria of the CEA Registry, we may have biased our results towards a higher-quality score. However, similar reviews have observed equally high qualities when primarily using databases such as MEDLINE. 2, 3 The QHES tool values the design and reporting of cost-effectiveness studies; therefore, it is possible that a study lost points for not being explicit in its reporting of study design and results. The quality scores are certainly susceptible to the biases of the individual assessor; however, we ensured at least a 90% inter-rater agreement across two reviewers. Since the QHES values reporting of study design, it gives equal weight to methodologies without considering their relative limitations, which can add analytical bias to our study and the resultant clinical implications. Given the limited cross comparability of the source studies, we were limited in our abilities to account for a number of data domains pertinent to cost-effectiveness studies, including patient choice and surgeon familiarity. In addition, it is not clear whether QALYs and existing cost methodologies are sensitive enough to detect differences in upper limb orthopaedic pathology; there is a need for greater study in these domains.
Cost-effectiveness is an area of increasing interest in upper limb orthopaedic surgery, especially in the shoulder and the wrist. We observe a high quality of CEAs in upper limb surgery since 1997, but a growing proportion of lower quality studies in recent years. It will be important to monitor the ongoing quality of CEAs in orthopaedics and ensure proper peer-review of future studies based on the Second Panel recommendations to ensure standards of reporting and comparability.
Take home message
-The current quality of cost-utility analyses in the field of hand and upper limb orthopaedic surgery is high.
-Over time, a greater proportion of hand and upper limb cost-utility analyses have demonstrated poorer quality scores, owing to a lack of reporting of certain key study parameters. -It will be important to monitor the ongoing quality of cost-utility analyses in orthopaedics and to ensure standards of reporting and comparability.
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